Activiomics, UCB Collaborate on Cell-Signaling Pathway Activity

Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.